Skip to main content
Equibles
SHC logo

SHC · Sotera Health Co

Track SHC — free

Use SHC with AI

Ask our own analyst here, or connect this data to the AI you already use.

Ask ALVIS about SHC

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

or use your own AI

The free Equibles MCP server lets any client query SEC filings, earnings calls, KPIs, holdings and prices directly — read-only, OAuth-secured, cited to the filing.

ChatGPT Claude Gemini
Server URL
https://mcp.equibles.com/mcp
All connection guides →
$19.48 -0.06 (-0.31%) At close · Aug 27
Market Cap
$5.58B
Shares
285.37M

Price & Indicators

Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$19.48 Open$19.55 Day$19.46–19.72 52W close$13.13–19.57 Avg vol 30d3.0M Short int12.1M · 4.2% float · 4.2d Short vol65% Last earningsAug 6, 2026 DataNov 2020–Aug 2026 Filing10-Q · Aug 6

Up next

Next earnings call
Nov 5, 2026 Est · unconfirmed · in 10 wks
FQ3-26 quarter ends
~Sep 30, 2026 Est
Latest filing: 10-Q
filed Aug 6, 2026

AI Brief

TL;DR.

Bullish
    Bearish

      AI-generated from the earnings call and 8-K · may contain errors · not investment advice

      Ask ALVIS about this →

      Equibles Rating

      blended score · not investment advice
      Overall
      Buy
      SellHoldBuy
      Technical Strong Buy Momentum Very Strong Sentiment Bullish Fundamentals Strong Quant / Vol Moderate
      Market backdrop VIX 14.5 · calm Equity put/call 0.39
      Technical
      price trend
      Strong Buy
      50 / 200-day cross No cross
      Price vs 200-day avg +17%
      above
      Price vs 50-day avg +8%
      above
      RSI (14) 63
      neutral
      MACD trend Positive
      52-week position 99%
      near high
      Volume (OBV) Confirms
      volume backs price
      Momentum
      relative strength
      Very Strong
      1-month return +9%
      trailing
      6-month return +33%
      trailing
      YTD return +10%
      this year
      Relative strength +18%
      vs S&P · 6-mo
      Sentiment
      smart money
      Bullish
      Trend (MA cross) No cross
      50d $18 › 200d $17 — 50d above 200d
      Institutional flow Accumulating
      +6% holders QoQ · +58 funds added
      Insider flow Distributing
      Net -$24.0M over 90 days · 100% sells
      Short interest Falling
      4.25% of float · ▼ -15.7% MoM · 4.2 days cover
      Volume signal Normal
      Volume near normal
      Institution breadth Multi-yr high
      316 holders — near 3-yr high, broad support
      Squeeze score 60
      elevated · 0–100
      Fundamentals
      Strong
      Revenue growth +6%
      Y/Y
      Gross margin 55%
      expanding
      EPS growth +69%
      Y/Y
      Free cash flow $149.2M
      Valuation P/E 34.3
      in line
      Balance sheet $1.8B
      net debt
      Quant / Vol
      risk profile
      Moderate
      Volatility 29%
      annualized · 1-yr
      Max drawdown −32%
      past year
      ATR 2.5%
      of price · 14-day

      Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

      Guidance & track record

      Beat or met 2 of last 4
      Latest guidance · from the Earnings Call filed Aug 6, 2026
      full-year 2026
      Total company revenue Initiated $1.24B – $1.25B
      prior FY $1.16B midpoint +7.0% Y/Y
      Constant currency revenue growth Initiated 5.25% – 6.75%
      Constant currency adjusted EBITDA growth Initiated 5.75% – 7.25%
      Adjusted EBITDA Initiated $634M – $643M
      Interest expense Lowered $135M – $142M
      May 5, 2026 $135M – $145M changed to Aug 6, 2026 $135M – $142M
      Effective tax rate applicable to adjusted net income Initiated 27% – 28%
      Capital expenditures Raised $200M – $225M
      May 5, 2026 $175M – $225M changed to Aug 6, 2026 $200M – $225M
      Adjusted EPS Initiated $0.95 – $1.01
      prior FY $0.27 midpoint +263.0% Y/Y
      full year
      Total company pricing improvement 3% – 4%
      the year
      Total company improvement of pricing 3% – 4%
      Prior guidance period ended · from the 8-K filed Nov 4, 2025
      Interest Expense · Full-Year 2025 $154M – $158M
      Adjusted EPS · Full-Year 2025 $0.81 – $0.86
      Capital expenditures · Full-Year 2025 $125M – $135M
      Guided vs delivered · last 4 settled
      Adjusted EPS Full-Year 2025
      guided $0.81 – $0.86
      $0.27 Miss −67.7%
      Adjusted EPS full year 2024
      guided $0.67 – $0.75
      $0.16 Miss −77.5%
      Total revenues full year 2023
      guided $1.04B – $1.06B
      $1.05B In line
      Total net revenues full-year 2022
      guided $995M – $1.01B
      $1B In line

      Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

      Technicals

      trend & momentum for long-term holders Strong Buy
      0 · 3 · 4
      50 / 200-day cross
      No cross Neutral
      Price vs 200-day avg
      +17% Bullish
      Price vs 50-day avg
      +8% Bullish
      RSI (14)
      63 Neutral
      MACD trend
      Positive Bullish
      52-week position
      99% Bullish
      Volume (OBV)
      Confirms Neutral
      Market signals — smart money & positioning
      Bullish · 3 of 6
      Trend (MA cross) No cross
      50d $18 › 200d $17 — 50d above 200d
      Institutional flow Accumulating
      +6% holders QoQ · +58 funds added
      Insider flow Distributing
      Net -$24.0M over 90 days · 100% sells
      Short interest Falling
      4.25% of float · ▼ -15.7% MoM · 4.2 days cover
      Volume signal Normal
      Volume near normal
      Institution breadth Multi-yr high
      316 holders — near 3-yr high, broad support
      Price context
      position in its 52-week range
      Range low $13 Now $19 · 99% Range high $20
      vs 200-day avg +17% vs 50-day avg +8%

      Illustrative technical + ownership context — a signal mix, not investment advice.

      Key metrics

      the company's own KPIs, from written earnings releases and filings
      Metric Latest Period YoY
      Net Debt non-GAAP 1.89B Year Ended December 31, 2025 —
      Total Debt non-GAAP 2.24B Year Ended December 31, 2025 —

      Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

      Versus peers

      Diagnostics & Research — same industry group
      Open screener →
      Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
      SHC
      Sotera Health Co
      this stock
      		$5.58B +10.4% +5.7% 34.3 4.2%
      TMO
      Thermo Fisher Scientific Inc.
      		 $234.31B +8.8% +14.5% 34.1 1.3%
      DHR
      Danaher Corp /De/
      		 $151.51B -5.8% +8.5% 38.2 1.2%
      NTRA
      Natera, Inc.
      		 $48.75B +47.8% -2.8% — 3.0%
      A
      Agilent Technologies, Inc.
      		 $43.80B +15.9% +6.4% 31.1 1.8%

      Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

      At a glance

      key data from every section
      Ownership
      Institutional Holders Accumulating
      Holders
      316
      % held
      102.2%
      Net QoQ
      +16.1M sh
      Top holder
      Sessa Capital IM, L.P.
      Held Float
      View
      Held by Funds
      Fund positions
      293
      View
      Short & Settlement
      Short Interest Falling
      Shares short
      12.1M
      Days to cover
      4.2d
      Change
      -2.3M sh
      View
      Short Volume
      Short vol %
      65%
      As of
      Aug 27, 2026
      Short Total
      View
      Fails to Deliver
      FTD shares
      513
      Value
      $9.0K
      As of
      Jul 30, 2026
      View
      Off-Exchange
      Off-exchange %
      38.2%
      Week of
      Jul 20, 2026
      Off-exch Lit
      View
      Smart Money
      Insider Trades Net selling
      Net (90d)
      -$24.0M
      Buyers / Sellers
      0 / 2
      Buyers Sellers
      View
      Financials
      Financials
      Revenue (FY)
      $1.2B
      Net income (FY)
      $77.9M
      EPS diluted
      $0.27
      View
      Filings
      SEC Filings
      Latest
      8-K
      Filed
      Aug 14, 2026
      This year
      17
      View
      Proposed Sales
      Value
      $2.8M
      Shares
      150.0K
      Filed
      Aug 7, 2026
      View
      Earnings & Events
      Earnings Calls Upcoming
      Next call
      Sep 9, 2026
      Last call
      Aug 6, 2026
      View
      Investor Relations
      Latest news
      Sotera Health Delivers Strong Sec…
      Published
      Aug 6, 2026
      Upcoming events
      1
      View

      Performance

      5D 20D 120D MTD YTD
      SHC +1.4% +9.1% +32.9% +9.1% +10.4%
      SPY +1.1% +4.0% +14.7% +3.2% +13.1%
      vs SPY +0.2% +5.2% +18.2% +5.9% -2.7%
      Key facts CIK 1822479 CUSIP 83601L102 13F (30d) 261 filings 257 filers Visit website Investor relations

      Report a Problem

      Category
      Description
      Email (optional, for follow-up)